Sihuan Of China Loses Premier's Son As Investor With IPO Move
This article was originally published in PharmAsia News
China's Sihuan Pharmaceutical Holdings Group lost one of its major investors when a prominent co-founder's firm sold its shares
You may also be interested in...
The failure of the SGLT2 inhibitor is not unexpected, but allays any concerns that it could have worsened outcomes for patients with hypertension or heart disease.
After a year that French industry association Gemme says has demonstrated the importance of a sustainable generics sector, the market continued to grow purely due to the contribution made by newly genericized molecules.
Henlius has announced plans to seeing its sales shoot up in 2020 based on three new launches.